Cobo-Calvo, Alvaro
Sepúlveda, María
Rollot, Fabien
Armangué, Thais
Ruiz, Anne
Maillart, Elisabeth
Papeix, Caroline
Audoin, Bertrand
Zephir, Helene
Biotti, Damien
Ciron, Jonathan
Durand-Dubief, Francoise
Collongues, Nicolas
Ayrignac, Xavier
Labauge, Pierre
Thouvenot, Eric
Bourre, Bertrand
Montcuquet, Alexis
Cohen, Mikael
Deschamps, Romain
Solà-Valls, Nuria
Llufriu, Sara
De Seze, Jerome
Blanco, Yolanda
Vukusic, Sandra
Saiz, Albert
Marignier, Romain
Article History
Received: 21 December 2018
Accepted: 19 June 2019
First Online: 2 July 2019
Ethics approval and consent to participate
: The study was approved by the ethics committee of the University Hospital of Lyon, France, and Hospital Clinic of Barcelona, Spain. All patients gave their informed consent to participate in the study.
: Not applicable
: Cobo-Calvo has received a grant from Fundación Alfonso Martin Escudero. Sepulveda, Fabien Rollot, Armangué, Ruiz, Maillart, Papeix , Audoin and Zephir declare that they have no competing interests. Biotti has received consulting and lecturing fees and travel grants from Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma. Ciron serves on scientific advisory board for Merck Serono and Roche, and has received funding for travel and honoraria from Biogen, Novartis, Genzyme, Teva Pharmaceuticals, Merck Serono and Roche, with no relation with the submitted work. Durand-Dubief serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Roche and Teva. Collongues declares no competing interests. Ayrignac declares no competing interests. Labauge and Thouvenot declare that they have no competing interests. Bourre has received consulting and lecturing fees, travel grants and research support from Biogen, Genzyme, Novartis, Merck Serono, Roche, Sanofi and Teva Pharma. Montcuquet has received funding for travel from Merck Serono, Teva, Novartis, Sanofi-Genzyme and Biogen. Cohen received honoraria for participation to advisory boards from Biogen, Novartis, Roche and Ad Scientam, with no relation to this study. Deschamps declares no competing interests. Solà-Valls receives funding from the Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (FEDER) (FI16/00251), Predoctoral Grant for Health Research (PFIS). Llufriu, De Seze and Blanco declare that they have no competing interests. Vukusic has received consulting and lecturing fees, travel grants and research support from Biogen, Geneuro, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharm. Saiz has received travel funding and/or speaker honoraria from Bayer-Schering, Merck-Serono, Biogen Idec, Sanofi-Aventis,Teva Pharmaceutical Industries, Novartis and Roche. Marignier has received consulting and lecturing fees, travel grants and research support from Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma.